Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients.

IF 4 3区医学 Q2 VIROLOGY

Virology Journal Pub Date : 2025-06-24 DOI:10.1186/s12985-025-02778-8

Tania Portella Costa, Dayanne Mozaner Bordin, Mateus Nóbrega Aoki, Lucas Blanes

{"title":"Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients.","authors":"Tania Portella Costa, Dayanne Mozaner Bordin, Mateus Nóbrega Aoki, Lucas Blanes","doi":"10.1186/s12985-025-02778-8","DOIUrl":null,"url":null,"abstract":"Purpose: Convalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil.Methods: This retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements.Results: Patients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects.Conclusions: Our findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP's mechanisms of action and its integration into broader therapeutic strategies.","PeriodicalId":23616,"journal":{"name":"Virology Journal","volume":"22 1","pages":"206"},"PeriodicalIF":4.0000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12186417/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Virology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12985-025-02778-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"VIROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Convalescent plasma (CP), obtained from individuals who have recovered from COVID-19, has been widely explored as a potential therapeutic option, particularly in the absence of vaccines and monoclonal antibody treatments. This study aimed to evaluate the effectiveness of CP therapy in improving survival among non-immunized COVID-19 patients hospitalized in Brazil.

Methods: This retrospective unicentric cohort study was conducted at a private hospital in Campo Largo, Paraná, Brazil, from July 2020 to February 2021. A total of 245 hospitalized COVID-19 patients were included, confirmed by RT-qPCR or antigen testing. Patients were divided into two groups: those receiving CP alongside standard treatment (n=100) and those receiving standard treatment alone (n=145). Survival outcomes were assessed using Kaplan-Meier analysis and Cox regression, while inflammatory responses were evaluated through C-reactive protein (CRP) measurements.

Results: Patients treated with CP had a significantly higher survival rate (91%) compared to the control group (82.8%) (P=0.0363). The survival benefit persisted throughout the follow-up period, with a 2.25-fold lower risk of death in the CP group after adjusting for age (P=0.0480). However, no significant differences in CRP levels were observed between groups at discharge, suggesting that CP's benefits may be mediated through immune modulation rather than direct anti-inflammatory effects.

Conclusions: Our findings indicate that CP therapy significantly improves survival in non-immunized COVID-19 patients, reinforcing its potential role in settings with limited access to advanced treatments. Future studies should explore CP's mechanisms of action and its integration into broader therapeutic strategies.

查看原文本刊更多论文

恢复期血浆治疗提高未免疫COVID-19患者生存率的疗效观察

目的：从COVID-19康复个体中获得的恢复期血浆（CP）已被广泛探索作为一种潜在的治疗选择，特别是在缺乏疫苗和单克隆抗体治疗的情况下。本研究旨在评估CP治疗在提高巴西未接种疫苗的COVID-19住院患者生存率方面的有效性。方法：这项回顾性单中心队列研究于2020年7月至2021年2月在巴西帕拉纳 Campo Largo的一家私立医院进行。共纳入245例住院新冠肺炎患者，经RT-qPCR或抗原检测确诊。患者分为两组：在标准治疗的同时接受CP治疗组（n=100）和单独接受标准治疗组（n=145）。使用Kaplan-Meier分析和Cox回归评估生存结果，同时通过c反应蛋白（CRP）测量评估炎症反应。结果：CP组患者生存率（91%）明显高于对照组（82.8%）（P=0.0363）。在整个随访期间，生存获益持续存在，经年龄调整后，CP组的死亡风险降低2.25倍（P=0.0480）。然而，出院时两组之间CRP水平没有显著差异，这表明CP的益处可能是通过免疫调节介导的，而不是直接的抗炎作用。结论：我们的研究结果表明，CP治疗可显着提高未免疫的COVID-19患者的生存率，从而增强了其在无法获得先进治疗的环境中的潜在作用。未来的研究应该探索CP的作用机制及其与更广泛的治疗策略的结合。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Virology Journal 医学-病毒学

CiteScore

7.40

自引率

2.10%

发文量

186

审稿时长

1 months

期刊介绍： Virology Journal is an open access, peer reviewed journal that considers articles on all aspects of virology, including research on the viruses of animals, plants and microbes. The journal welcomes basic research as well as pre-clinical and clinical studies of novel diagnostic tools, vaccines and anti-viral therapies. The Editorial policy of Virology Journal is to publish all research which is assessed by peer reviewers to be a coherent and sound addition to the scientific literature, and puts less emphasis on interest levels or perceived impact.